{"protocolSection": {"identificationModule": {"nctId": "NCT00442338", "orgStudyIdInfo": {"id": "0476-334"}, "secondaryIdInfos": [{"id": "MK-0476-334"}, {"id": "2007_007"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)", "officialTitle": "MK-476 IV Formulation Phase III Open Label Exploratory Comparative Study - Acute Exacerbations of Asthma -"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-03"}, "primaryCompletionDateStruct": {"date": "2007-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-02-27", "studyFirstSubmitQcDate": "2007-02-27", "studyFirstPostDateStruct": {"date": "2007-03-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-22", "resultsFirstSubmitQcDate": "2009-05-22", "resultsFirstPostDateStruct": {"date": "2009-07-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-01-31", "lastUpdatePostDateStruct": {"date": "2022-02-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 91, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Montelukast 7 mg", "type": "EXPERIMENTAL", "description": "Montelukast 7 mg IV administration", "interventionNames": ["Drug: montelukast sodium"]}, {"label": "Montelukast 14 mg", "type": "EXPERIMENTAL", "description": "Montelukast 14 mg IV administration", "interventionNames": ["Drug: montelukast sodium"]}, {"label": "Aminophylline 250 mg", "type": "ACTIVE_COMPARATOR", "description": "Aminophylline 250 mg IV drip administration", "interventionNames": ["Drug: aminophylline hydrate"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes", "armGroupLabels": ["Montelukast 7 mg"], "otherNames": ["MK-0476"]}, {"type": "DRUG", "name": "montelukast sodium", "description": "Montelukast 14 mg single injection (IV bolus administration) over 5 minutes", "armGroupLabels": ["Montelukast 14 mg"], "otherNames": ["MK-0476"]}, {"type": "DRUG", "name": "aminophylline hydrate", "description": "Aminophylline 250 mg IV drip infusion over 60 minutes", "armGroupLabels": ["Aminophylline 250 mg"], "otherNames": ["Kyophyllin\u00ae Injection 2.5%, FK05"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration", "description": "The time weighted average change from Baseline in Forced Expiratory Volume in One Second (FEV1) over the first 60 minutes after study drug administration (average change FEV1 (0-60 min)). Baseline (pre-allocation) was the last measurement obtained during the screening period.", "timeFrame": "Baseline and 60 minutes after study drug administration"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adult participants with acute asthma attacks\n\nExclusion Criteria:\n\n* Participant has any known or suspected, acute or chronic cause for their pulmonary symptoms other than asthma (e.g., COPD, chronic heart failure, etc.).\n* Participant has a smoking habit (15 cigarettes per day) within a month prior to screening period, and/or has a smoking history (20 cigarettes per day) of more than 15 years.\n* Participant has a disease of the cardiovascular, hepatic, renal, hematologic systems, or other severe disease.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with acute exacerbation of bronchial asthma received standard treatments of inhaled \u03b2-agonist or oxygen inhalation to treat the acute exacerbations during the 60 minutes in the screening period before the study randomization.", "recruitmentDetails": "Phase III.\n\nStudied period: March 12, 2007 (date study drug was first administered to first participant) to August 1, 2007 (date study drug was last administered to last participant). Study was conducted at 31 clinical sites.", "groups": [{"id": "FG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg IV Administration"}, {"id": "FG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg Intravenous Administration"}, {"id": "FG002", "title": "Aminophylline 250 mg", "description": "Aminophylline 250 mg IV drip administration"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}, {"groupId": "FG002", "numSubjects": "31"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}, {"groupId": "FG002", "numSubjects": "31"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg IV Administration"}, {"id": "BG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg Intravenous Administration"}, {"id": "BG002", "title": "Aminophylline 250 mg", "description": "Aminophylline 250 mg IV drip administration"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "91"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.0", "spread": "12.3"}, {"groupId": "BG001", "value": "56.7", "spread": "15.2"}, {"groupId": "BG002", "value": "55.4", "spread": "14.5"}, {"groupId": "BG003", "value": "56.0", "spread": "13.9"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Adolescents (12-17 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "0", "spread": "12.3"}, {"groupId": "BG001", "value": "1", "spread": "15.2"}, {"groupId": "BG002", "value": "0", "spread": "14.5"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Adults (18-64 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "57"}]}]}, {"title": "From 65-84 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "33"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "62"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "29"}]}]}]}, {"title": "Asthma Attack Severity based on Asthma Prevention and Management Guideline 2003, Japan", "description": "Mild (Peak Expiratory Flow: 70%-80%), Moderate (Peak Expiratory Flow: 50%-70%), Severe (Peak Expiratory Flow: \\<=50%) or Serious (Peak Expiratory Flow: incapable measurement, cyanosis, head trip, disturbed consciousness, incontinence or asphyxia)", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Mild", "categories": [{"measurements": [{"groupId": "BG000", "value": "21", "spread": "0.29"}, {"groupId": "BG001", "value": "18", "spread": "0.33"}, {"groupId": "BG002", "value": "26", "spread": "0.53"}, {"groupId": "BG003", "value": "65"}]}]}, {"title": "Moderate", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "26"}]}]}, {"title": "Severe", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}, {"title": "Serious", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Baseline Forced Expiratory Volume in One Second (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.35", "spread": "0.29"}, {"groupId": "BG001", "value": "1.18", "spread": "0.33"}, {"groupId": "BG002", "value": "1.43", "spread": "0.53"}, {"groupId": "BG003", "value": "1.32", "spread": "0.41"}]}]}]}, {"title": "Duration of Asthma", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.9", "spread": "10.4"}, {"groupId": "BG001", "value": "13.9", "spread": "11.5"}, {"groupId": "BG002", "value": "16.7", "spread": "14.1"}, {"groupId": "BG003", "value": "15.2", "spread": "12.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration", "description": "The time weighted average change from Baseline in Forced Expiratory Volume in One Second (FEV1) over the first 60 minutes after study drug administration (average change FEV1 (0-60 min)). Baseline (pre-allocation) was the last measurement obtained during the screening period.", "populationDescription": "Per Protocol Set (PPS): subset of participants who comply with the protocol sufficiently to ensure that these data will likely exhibit effects of treatment, according to the underlying scientific model. Aminophylline 250 mg - 1 participant with no FEV1 data at 60 minutes was excluded from the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 60 minutes after study drug administration", "groups": [{"id": "OG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg IV Administration"}, {"id": "OG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg IV Administration"}, {"id": "OG002", "title": "Aminophylline 250 mg", "description": "Aminophylline 250 mg IV drip administration"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "lowerLimit": "0.02", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "0.00", "upperLimit": "0.11"}, {"groupId": "OG002", "value": "0.06", "lowerLimit": "0.01", "upperLimit": "0.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Treatment difference in change from Baseline in FEV1 within the first 60 minutes after study drug administration was assessed as the difference in the least square (LS) means of time weighted average change FEV1 (0-60 min) using an Analysis of Covariance (ANCOVA) model.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.871", "statisticalMethod": "ANCOVA", "statisticalComment": "The model included a factor for treatment and used the baseline FEV1 as a covariate.", "paramType": "Difference in LS Means", "paramValue": "0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.07", "ciUpperLimit": "0.08"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Treatment difference in change from Baseline in FEV1 within the first 60 minutes after study drug administration was assessed as the difference in the LS means of time weighted average change FEV1 (0-60 min) using an ANCOVA model.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.794", "statisticalMethod": "ANCOVA", "statisticalComment": "The model included a factor for treatment and used the baseline FEV1 as a covariate.", "paramType": "Difference in LS Means", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.06"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in change from Baseline in FEV1 within the first 60 minutes after study drug administration was assessed as the difference in the LS means of time weighted average change FEV1 (0-60 min) using an ANCOVA model.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.675", "statisticalMethod": "ANCOVA", "statisticalComment": "The model included a factor for treatment and used the baseline FEV1 as a covariate.", "paramType": "Difference in LS Means", "paramValue": "0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.09"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From Screening through post-trial visit (up to 14 days)", "eventGroups": [{"id": "EG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg IV Administration", "seriousNumAffected": 3, "seriousNumAtRisk": 30, "otherNumAffected": 5, "otherNumAtRisk": 30}, {"id": "EG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg Intravenous Administration", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 1, "otherNumAtRisk": 30}, {"id": "EG002", "title": "Aminophylline 250 mg", "description": "Aminophylline 250 mg IV drip administration", "seriousNumAffected": 1, "seriousNumAtRisk": 31, "otherNumAffected": 3, "otherNumAtRisk": 31}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}], "otherEvents": [{"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Glucose urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 31}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Japan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000628", "term": "Aminophylline"}, {"id": "D000013806", "term": "Theophylline"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000002316", "term": "Cardiotonic Agents"}, {"id": "D000010726", "term": "Phosphodiesterase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000058915", "term": "Purinergic P1 Receptor Antagonists"}, {"id": "D000058914", "term": "Purinergic Antagonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M3966", "name": "Aminophylline", "asFound": "Chest CT", "relevance": "HIGH"}, {"id": "M16573", "name": "Theophylline", "asFound": "Joint Infiltration", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M5572", "name": "Cardiotonic Agents", "relevance": "LOW"}, {"id": "M13629", "name": "Phosphodiesterase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}